- Home
- BL vs GENB Comparison
BL vs GENB Comparison
Compare BL & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BL | GENB |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | BL | GENB |
|---|---|---|
| Price | $28.44 | $12.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $56.62 | $23.20 |
| AVG Volume (30 Days) | ★ 1.5M | 718.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $177,031,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $10.90 | $16.58 |
| P/E Ratio | $220.85 | ★ N/A |
| Revenue Growth | ★ 43.78 | N/A |
| 52 Week Low | $24.70 | $11.00 |
| 52 Week High | $59.57 | $16.75 |
Technical Indicators
Market Signals| Indicator | BL | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 46.20 |
| Support Level | $25.49 | $11.63 |
| Resistance Level | $30.93 | $13.76 |
| Average True Range (ATR) | 1.96 | 1.31 |
| MACD | 0.21 | -0.12 |
| Stochastic Oscillator | 41.75 | 19.76 |
Price Performance
Historical ComparisonAbout BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.